Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

First nasal spray to treat Covid-19 in adults is here. Pharma company Glenmark has launched Nitric Oxide Nasal Spray, called FabiSpray in India, in partnership with SaNOtize.
The makers say that the spray will treat adult patients suffering from Covid-10, news agency ANI has reported.
Glenmark received manufacturing and marketing approval from India's drug regulator for Nitric Oxide Nasal Spray as part of the accelerated approval process.
The company said that phase 3 trial in India demonstrated reduction of viral load by 94 per cent in 24 hours and 99 per cent in 48 hours. "Nitric Oxide Nasal Spray was safe and well-tolerated in Covid-19 patients," an official statement said.
The company claims that when the Nitric Oxide Nasal is sprayed over nasal mucosa it acts as a physical and chemical barrier against the virus.
"FabiSpray is designed to kill the Covid-19 virus in the upper airways. When sprayed over nasal mucosa, it acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs," the statement said.
Terming the spray an effective and safe antiviral treatment for Covid-19, Glenmark Pharmaceuticals Ltd's Chief Commercial Officer Robert Crockart said "we are confident it will offer patients a much needed and timely therapy option."

First Nasal spray to treat Covid-19 launched in India. Check out details here

First Nasal spray to treat Covid&nbsp;patients launched in India
FabiSpray&nbsp;launched by Glenmark&nbsp;in partnership with SaNOtize
"Reduces viral load by 94% in 24 hours and 99% in 48 hours"
FabiSpray is designed to kill the COVID-19 virus in the upper airways
Company says the spray an effective and safe Covid treatment

Pharma company Glenmark has launched Nitric Oxide Nasal Spray, called FabiSpray in India, in partnership with SaNOtize.

First nasal spray to treat Covid-19 in adults is here. Pharma company Glenmark has launched Nitric Oxide Nasal Spray, called FabiSpray in India, in partnership with SaNOtize.
The makers say that the spray will treat adult patients suffering from Covid-10, news agency ANI has reported.
Glenmark received manufacturing and marketing approval from India's drug regulator for Nitric Oxide Nasal Spray as part of the accelerated approval process.
The company said that phase 3 trial in India demonstrated reduction of viral load by 94 per cent in 24 hours and 99 per cent in 48 hours. "Nitric Oxide Nasal Spray was safe and well-tolerated in Covid-19 patients," an official statement said.
The company claims that when the Nitric Oxide Nasal is sprayed over nasal mucosa it acts as a physical and chemical barrier against the virus.
"FabiSpray is designed to kill the Covid-19 virus in the upper airways. When sprayed over nasal mucosa, it acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs," the statement said.
Terming the spray an effective and safe antiviral treatment for Covid-19, Glenmark Pharmaceuticals Ltd's Chief Commercial Officer Robert Crockart said "we are confident it will offer patients a much needed and timely therapy option."

Molnupiravir: All you need to know about the anti-Covid pill
Approved for use in the UK, likely to get nod in India soon
First oral medicine in the world to be approved for use against Covid
Developed by the pharmaceutical companies Ridgeback Biotherapeutics and Merck, Sharp and Dohme
The antiviral drug molnupiravir was originally developed to treat the flu
Meant for adults at risk for progressing to severe Covid or hospitalisation
To be given to patients within 5 days of symptoms appearing
Will be given twice a day to patients recently diagnosed with Covid
Molnupiravir works by disrupting the virus’s reproduction.
Reduces the risk of hospitalisation or Covid death by 50%
Ineffective if it’s taken after the patient is hospitalised
The treatment can be given to both vaccinated and unvaccinated patients

Molnupiravir: All you need to know about the oral anti-Covid pill

Molnupiravir: All you need to know about the new anti-Covid pill

Molnupiravir: All you need to know about the anti-Covid pill

Molnupiravir: All you need to know about the anti-Covid pill
Approved for use in the UK, likely to get nod in India soon
First oral medicine in the world to be approved for use against Covid
Developed by the pharmaceutical companies Ridgeback Biotherapeutics and Merck, Sharp and Dohme
The antiviral drug Molnupiravir was originally developed to treat the flu
Meant for adults at risk for progressing to severe Covid or hospitalisation
To be given to patients within 5 days of symptoms appearing
Will be given twice a day to patients recently diagnosed with Covid
Molnupiravir works by disrupting the virus&rsquo;s reproduction
Reduces the risk of hospitalisation or Covid death by 50%
Ineffective if it&rsquo;s taken after the patient is hospitalised
The treatment can be given to both vaccinated and unvaccinated patients

The antiviral drug Molnupiravir was originally developed to treat the flu. It's meant for adults at risk for progressing to severe Covid or hospitalisation

World's first oral anti-Covid&nbsp;pill,&nbsp;Molnupiravir, has been approved by the UK and is likely to green light in India soon. It's been hailed as a gamechanger&nbsp;in the fight against Covid-19.&nbsp;
<h3>Here's all you need to know about the anti-Covid pill:</h3>
<ul>
<li>Approved for use in the UK, likely to get nod in India soon</li>
<li>First oral medicine in the world to be approved for use against Covid</li>
<li>Developed by the pharmaceutical companies Ridgeback Biotherapeutics and Merck, Sharp and Dohme</li>
<li>The antiviral drug molnupiravir was originally developed to treat the flu</li>
<li>Meant for adults at risk for progressing to severe Covid or hospitalisation</li>
<li>To be given to patients within 5 days of symptoms appearing</li>
<li>Will be given twice a day to patients recently diagnosed with Covid</li>
<li>Molnupiravir works by disrupting the virus&rsquo;s reproduction.</li>
<li>Reduces the risk of hospitalisation or Covid death by 50%</li>
<li>Ineffective if it&rsquo;s taken after the patient is hospitalised</li>
<li>The <a href="https://www.editorji.com/coronavirus/govt-issues-new-guidelines-for-covid-19-treatment-here-s-all-you-need-to-know-1642475667411" target="_blank">treatment</a> can be given to both vaccinated and unvaccinated patients</li>
</ul>
Also Read:&nbsp;<a href="https://www.editorji.com/india-news/oral-anti-covid-pill-may-be-cleared-for-use-within-days-report-1636597101954" target="_blank">Oral anti-Covid pill may be cleared for use within days: report</a>

Oral antiviral medicine for the treatment of mild-to-moderate Covid-19 is likely to get approval "within days", NDTV has reported. Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR, told NDTV on Wednesday that the Merck drug Molnupiravir is likely to get the Emergency use authorisation very soon.
The medicine is meant for adults who are at risk for progressing to severe Covid-19 or hospitalization. Another pill from Pfizer, Paxlovid, may take some more time, Vishwakarm added.
The two drugs, he said, will make a difference and "as we move from pandemic to endemic, these are the ones which are going to be more important than vaccination".
Dr Vishwakarma called the drugs the "final nail in the coffin of the virus by science".
UK medicines regulator had approved Molnupiravir last week. The tablet will be given twice a day to vulnerable patients recently diagnosed with the disease.
In clinical trials the pill, originally developed to treat flu, cut the risk of hospitalisation or death by about half.
DR Vishakarma further said that medicine might initially cost "2000 to 4000 rupees per cycle of treatment, then it will come down to 500 to 600 or 1,000 rupees".

Oral anti-Covid pill may be cleared for use within days: report

An oral pill for the treatment of mild-to-moderate Covid-19 is likely to get approval "within days". Know details


Oral anti-Covid pill may be cleared for use within days

Oral antiviral medicine for the treatment of mild-to-moderate Covid-19 is likely to get approval "within days", NDTV has reported. Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR, told NDTV on Wednesday that the Merck drug Molnupiravir is likely to get the Emergency use authorisation very soon.
The medicine is meant for adults who are at risk for progressing to severe Covid-19 or hospitalization. Another pill from Pfizer, Paxlovid, may take some more time, Dr&nbsp;Vishwakarm added.
The two drugs, he said, will make a difference and "as we move from pandemic to endemic, these are the ones which are going to be more important than vaccination".
Dr Vishwakarma called the drugs the "final nail in the coffin of the virus by science".
UK medicines regulator had approved Molnupiravir last week. The tablet will be given twice a day to vulnerable patients recently diagnosed with the disease.

Merck oral pill&nbsp;Molnupiravir is likely to get the Emergency use authorisation very soon in India, says&nbsp;Chairman of the Covid Strategy Group

Oral antiviral medicine for the treatment of mild-to-moderate Covid-19 is likely to get approval "within days", NDTV has reported. Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR, told NDTV on Wednesday that the Merck drug Molnupiravir is likely to get the Emergency use authorisation very soon.
The medicine is meant for adults who are at risk for progressing to severe Covid-19 or hospitalization. Another pill from Pfizer, Paxlovid, may take some more time, Vishwakarm added.
The two drugs, he said, will make a difference and "as we move from pandemic to endemic, these are the ones which are going to be more important than vaccination".
Dr Vishwakarma called the drugs the "final nail in the coffin of the virus by science".
Also Read: <a href="https://www.editorji.com/in-depth/molnupiravir-all-you-need-to-know-about-the-oral-anti-covid-pill-1636605465191" target="_blank">What is Molnupiravir?&nbsp;</a>
UK medicines regulator had approved Molnupiravir last week. The tablet will be given twice a day to vulnerable patients recently diagnosed with the disease.
In clinical trials the pill, originally developed to treat flu, cut the risk of hospitalisation or death by about half.
DR Vishakarma further said that medicine might initially cost "2000 to 4000 rupees per cycle of treatment, then it will come down to 500 to 600 or 1,000 rupees".

Plasma therapy could be dropped from clinical management protocol of Covid-19 as ICMR&rsquo;s expert panel found that the therapy wasn&rsquo;t beneficial in reducing the progression to severe disease or death of patients, a CNN-News18 report said quoting sources.
The Indian Council of Medical Research is expected to issue an advisory on the same in the next few days. India&rsquo;s national task force on Covid-19 management met on Friday, to review the convalescent plasma therapy for infected patients. The present guidelines allow &ldquo;off label" use of plasma therapy at the stage of early moderate disease, that is, within seven days of the onset of Covid-19 symptoms and if there is availability of donor plasma.
A group of 18 clinicians, scientists and public health professionals had recently written to the government, saying the &ldquo;irrational use&rdquo; of plasma therapy &ldquo;raises the possibility of more virulent strains&rdquo; of Sars-Cov-2, the virus that causes Covid-19. In their letter, the experts cited three studies &mdash; the ICMR-PLACID Trial, the Recovery Trial conducted by the University of Oxford, and Argentina&rsquo;s PlasmAr Trial &mdash; to argue that the country&rsquo;s existing guidelines on plasma therapy were not based on evidence.

Plasma therapy to be dropped from ICMR's Covid protocols?

Plasma therapy may be dropped from ICMR's Covid&nbsp;management&nbsp;protocols, say reports; experts argue it may not be effective

Plasma therapy could be dropped from clinical management protocol of Covid-19 as ICMR&rsquo;s expert panel found that the therapy wasn&rsquo;t beneficial in reducing the progression to severe disease or death of patients, a CNN-News18 report said quoting sources.
The Indian Council of Medical Research is expected to issue an advisory on the same in the next few days. India&rsquo;s national task force on Covid-19 management met on Friday, to review the convalescent plasma therapy for infected patients. The present guidelines allow &ldquo;off label" use of plasma therapy at the stage of early moderate disease, that is, within seven days of the onset of Covid-19 symptoms and if there is availability of donor plasma.
A group of 18 clinicians, scientists and public health professionals had recently written to the government, saying the &ldquo;irrational use&rdquo; of plasma therapy &ldquo;raises the possibility of more virulent strains&rdquo; of Sars-Cov-2, the virus that causes Covid-19. In their letter, the experts cited three studies &mdash; the ICMR-PLACID Trial, the Recovery Trial conducted by the University of Oxford, and Argentina&rsquo;s PlasmAr Trial &mdash; to argue that the country&rsquo;s existing guidelines on plasma therapy were not based on evidence.

covid treatment

Categories